Quote:

---

Groundbreaking clinical trial achieves 100% remission rate for all cancer patients
This trial is significant because it paves the way for immunotherapy to be used as a first-line treatment for certain types of rectal cancer

---

Used only an anti-PD-1 blocker which is amazing. The longer term results - almost 50% of patients were still in remission in a median follow-up of 28.9 months which is still amazing. I have to wonder if leronlimab's downregulation of PD1/PD-L1 and it's other cancer fighting abilities could increase that 50% if leronlimab use was continued long term as adjuvant therapy.

Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer.